Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma

This review provides an overview of the adverse events associated with BRAFi and MEKi in melanoma, with a focus on the most commonly reported and serious adverse events, and offers practical guidance from a clinical perspective for optimal management.

http://ift.tt/2rxGexU